Back

CRISPR-inhibition screen for lncRNAs linked to melanoma growth and metastasis

Petroulia, S.; Hockemeyer, K.; Tiwari, S.; Berico, P.; Shamloo, S.; Banijamali, S. E.; Vega-Saenz de Miera, E.; Gong, Y.; Thandapani, P.; Wang, E.; Schulz, M.; Tsirigos, A.; Osman, I.; Aifantis, I.; Imig, J.

2024-07-24 cancer biology
10.1101/2024.07.24.604899 bioRxiv
Show abstract

Melanoma being one of the most common and deadliest skin cancers, has been rising since the past decade. Patients at advanced stages of the disease have very poor prognoses, as opposed to at the earlier stages. Nowadays the standard-of-care of advanced melanoma is resection followed by immune checkpoint inhibition based immunotherapy. However, a substantial proportion of patients either do not respond or develop resistances. This underscores a need for novel approaches and therapeutic targets as well as a better understanding of the mechanisms of melanoma pathogenesis. Long non-coding RNAs (lncRNAs) comprise a poorly characterized class of functional players and promising targets in promoting malignancy. Certain lncRNAs have been identified to play integral roles in melanoma progression and drug resistances, however systematic screens to uncover novel functional lncRNAs are scarce. Here, we profile differentially expressed lncRNAs in patient derived short-term metastatic cultures and BRAF-MEK-inhibition resistant cells. We conduct a focused growth-related CRISPR-inhibition screen of overexpressed lncRNAs, validate and functionally characterize lncRNA hits with respect to cellular growth, invasive capacities and apoptosis in vitro as well as the transcriptomic impact of our lead candidate the novel lncRNA XLOC_030781. In sum, we extend the current knowledge of ncRNAs and their potential relevance on melanoma. SignificancePreviously considered as transcriptional noise, lncRNAs have emerged as novel players in regulating many cellular aspects in health and disease including melanoma. However, the number and as well as the extent of functional significance of most lncRNAs remains elusive. We provide a comprehensive strategy to identify functionally relevant lncRNAs in melanoma by combining expression profiling with CRISPR-inhibition growths screens lowering the experimental effort. We also provide a larger resource of differentially expressed lncRNAs with potential implications in melanoma growth and invasion. Our results broaden the characterized of lncRNAs as potential targets for future therapeutic applications.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
Pigment Cell & Melanoma Research
11 papers in training set
Top 0.1%
14.1%
2
Journal of Investigative Dermatology
42 papers in training set
Top 0.1%
14.1%
3
Nature Communications
4913 papers in training set
Top 27%
6.7%
4
Scientific Reports
3102 papers in training set
Top 15%
6.7%
5
Cancers
200 papers in training set
Top 0.9%
6.2%
6
Experimental Dermatology
10 papers in training set
Top 0.1%
4.2%
50% of probability mass above
7
Journal of Translational Medicine
46 papers in training set
Top 0.2%
3.5%
8
PLOS ONE
4510 papers in training set
Top 49%
2.1%
9
eLife
5422 papers in training set
Top 36%
2.0%
10
PLOS Genetics
756 papers in training set
Top 7%
2.0%
11
Cell Reports
1338 papers in training set
Top 22%
1.9%
12
npj Genomic Medicine
33 papers in training set
Top 0.5%
1.5%
13
Frontiers in Genetics
197 papers in training set
Top 6%
1.5%
14
Molecular Cancer
14 papers in training set
Top 0.5%
1.3%
15
PeerJ
261 papers in training set
Top 9%
1.3%
16
PLOS Computational Biology
1633 papers in training set
Top 20%
1.2%
17
Oncogene
76 papers in training set
Top 1%
1.2%
18
Cancer Research
116 papers in training set
Top 3%
1.2%
19
Genome Medicine
154 papers in training set
Top 6%
1.2%
20
Cell Reports Medicine
140 papers in training set
Top 6%
0.9%
21
Cancer Research Communications
46 papers in training set
Top 1.0%
0.9%
22
International Journal of Cancer
42 papers in training set
Top 1%
0.8%
23
Life Science Alliance
263 papers in training set
Top 1%
0.8%
24
Communications Biology
886 papers in training set
Top 22%
0.8%
25
The Journal of Pathology
22 papers in training set
Top 0.4%
0.8%
26
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 43%
0.8%
27
BMC Cancer
52 papers in training set
Top 3%
0.7%
28
International Journal of Molecular Sciences
453 papers in training set
Top 16%
0.7%
29
iScience
1063 papers in training set
Top 33%
0.7%
30
European Journal of Cancer
10 papers in training set
Top 0.6%
0.7%